Genome Editing/Genome Engineering Market Report Provides Insights Into Market Evolution And Growth Prospects

The genome editing and genome engineering market is on track for remarkable expansion, driven by technological advancements and growing applications across medicine and agriculture. This sector is becoming increasingly vital as researchers and companies push the boundaries of gene modification to address a wide range of health and scientific challenges. Let's explore the market's valuation forecast, major players, current trends, and key segments shaping its future.

Projected Market Valuation and Growth Trajectory in Genome Editing and Engineering
The genome editing/genome engineering market is anticipated to experience significant growth in the coming years, reaching a valuation of $24.53 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 19.2%. The surge is largely fueled by several factors, including the translation of gene editing therapies into clinical settings, rapid expansion of agricultural genomics initiatives, enhancements in editing precision, establishment of ethical guidelines, and the increasing commercialization of genome editing services. Key trends expected to influence this growth include the widespread uptake of CRISPR-based technologies, broader utilization of genome editing in disease research, rising applications in cell line engineering, a greater emphasis on precision gene modification, and enhanced financial support from academic and governmental research bodies.

The genome editing/genome engineering market size has grown rapidly in recent years. It will grow from $10.17 billion in 2025 to $12.15 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to discovery of genome editing techniques, early research applications, availability of molecular biology tools, growth of academic research funding, demand for disease modeling.

Download a free sample of the genome editing/genome engineering market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8010&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the Genome Editing and Engineering Market
Several influential corporations play pivotal roles in the genome editing/genome engineering arena. These include Thermo Fisher Scientific Inc., Merck Group, Genscript Biotech Corp, Sangamo Therapeutics Inc., Lonza Group AG, Editas Medicine Inc., CRISPR Therapeutics AG, Agilent Technologies Inc., Intellia Therapeutics, bluebird bio Inc., Transposagen Biopharmaceuticals Inc., Tecan Trading AG, Precision BioSciences, PerkinElmer Inc., Cellectis S.A, Applied StemCell Inc., Bio-Rad Laboratories Inc., Bio-Techne, Creative Biogene, Cyagen Biosciences, Dharmacon Inc., Eurofins Genomics LLC, Evotec SE, GeneCopoeia Inc., Genewiz, Horizon Discovery Group PLC, Inscripta Inc., Integrated DNA Technologies Inc., MaxCyte Inc., New England Biolabs, and Novartis International AG.

A notable industry development occurred in February 2023 when Ensoma, a US-based genomic medicines firm focused on in vivo cell therapies, acquired Denmark-based Twelve Bio. Twelve Bio specializes in advanced CRISPR-Cas12a gene editing tools tailored for therapeutic applications. This acquisition aims to integrate Twelve Bio's next-generation CRISPR-Cas12a technology into Ensoma's Engenious platform, enhancing genome-engineering capabilities and accelerating the creation of in vivo genomic therapies, thereby reinforcing Ensoma's technological edge in the genome editing market.

View the full genome editing/genome engineering market report:
https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Current Trends Shaping the Genome Editing and Engineering Field
Strategic collaborations and partnerships are becoming increasingly common as companies seek to strengthen their foothold in this competitive market. Business alliances often involve formal agreements designed to combine complementary strengths and accelerate innovation. For example, in April 2024, Regeneron Pharmaceuticals, a US biopharmaceutical company with expertise in immunology, oncology, and genetic diseases, partnered with Mammoth Biosciences, a biotech enterprise founded by Jennifer Doudna that specializes in CRISPR-based gene editing technologies. This collaboration aims to leverage Mammoth's ultra-small CRISPR platforms alongside Regeneron's delivery mechanisms to speed up the development of in vivo gene editing therapies targeting tissues beyond the liver. This initiative expands Regeneron's therapeutic pipeline and technology capabilities. Mammoth Biosciences provides advanced CRISPR genome editing systems, including proprietary small Cas enzymes, for both therapeutic and diagnostic uses.

Emerging Innovations and Expanding Applications in Genome Editing
The integration of cutting-edge genome editing technologies is opening new avenues for research and clinical applications. More companies are focusing on precision gene modifications that address complex diseases and enable novel therapeutic options. Additionally, the growing emphasis on agricultural genomics is driving innovations that improve crop traits and sustainability. Funding from academic institutions and government research programs is increasing, which supports the development of sophisticated editing tools and expands the range of potential applications in biotechnology and pharmaceutical sectors.

Breakdown of Segments Covered in the Genome Editing and Engineering Report
This market report categorizes the genome editing/genome engineering sector into multiple segments for a detailed analysis:
1) By Product and Service: Reagents and Consumables, Software and Systems, Services
2) By Technology: CRISPR, TALEN, ZFN, Antisense, Other Technologies
3) By Application: Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery and Development, Other Applications
4) By End User: Biotechnology Companies, Pharmaceutical Companies, Academic and Government Research Institutes

Further segmentation includes:
- Reagents and Consumables such as CRISPR or Cas9 kits, TALENs kits, Zinc Finger Nucleases (ZFNs), donor DNA templates, and nucleotide reagents.
- Software and Systems comprising genome editing design software, analysis and visualization tools, and workflow management systems.
- Services encompassing gene synthesis and cloning, custom genome editing services, and consulting tailored to genome editing projects.

Together, these segments provide a comprehensive framework for understanding the diverse components and applications within the genome editing and genome engineering market.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.